Skip to main content

Table 8 Sample classification after LDA to discriminate between CSF samples from patients with Relapse–remitting multiple sclerosis (RRMS) and non-inflammatory diseases of the CNS (N-INF) based on the identified protein spots

From: Posttranslational modifications of proteins are key features in the identification of CSF biomarkers of multiple sclerosis

 

Classification resultsb,c

Disease

Predicted Group Membership

Total

RRMS

N-INF

Original

 Count

RRMS

67

2

69

N-INF

12

30

42

 %

RRMS

97.1

2.9

100

N-INF

28.6

71.4

100

Cross-validateda

 Count

RRMS

67

2

69

N-INF

14

28

42

 %

RRMS

97.1

2.9

100

N-INF

33.3

66.7

100

  1. aCross validation is done only for those cases in the analysis. In cross validation, each sample is classified by the functions derived from all samples other than the one under analysis
  2. b87.4% of original grouped cases correctly classified
  3. c85.6% of cross-validated grouped cases correctly classified
Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094